Inventor · disambiguated record
Upender Velaparthi
Also filed as: VELAPARTHI UPENDER
33 granted patents·11 pending applications·106 citations·filing 2002–2024
95Inventor score
Files withBRISTOL MYERS SQUIBB CO32VELAPARTHI UPENDER5RIGEL PHARMACEUTICALS INC4AUSTIN JOEL FRANCIS1JUNO THERAPEUTICS INC1
Top patents by PatentIndex Score
44 records- 0194US7534792B2Pyrrolotriazine kinase inhibitorsBRISTOL MYERS SQUIBB CO·Filed 2007·Granted May 19, 2009·30 cites·14 claims
- 0293US7223757B2Tyrosine kinase inhibitorsBRISTOL MYERS SQUIBB CO·Filed 2005·Granted May 29, 2007·16 cites·21 claims
- 0389US7879855B2Pyrrolotriazine kinase inhibitorsBRISTOL MYERS SQUIBB CO·Filed 2009·Granted Feb 1, 2011·10 cites·1 claims
- 0488US10669272B2Substituted naphthyridinone compounds useful as T cell activatorsBRISTOL MYERS SQUIBB CO·Filed 2019·Granted Jun 2, 2020·4 cites·13 claims
- 0585US11866430B2Naphthyridinone compounds useful as T cell activatorsBRISTOL MYERS SQUIBB CO·Filed 2019·Granted Jan 9, 2024·3 cites·11 claims
- 0682US9556179B2Substituted imidazoles as casein kinase 1 D/E inhibitorsBRISTOL MYERS SQUIBB CO·Filed 2013·Granted Jan 31, 2017·9 cites·15 claims
- 0780US7232826B2Tyrosine kinase inhibitorsBRISTOL MYERS SQUIBB CO·Filed 2003·Granted Jun 19, 2007·13 cites·2 claims
- 0880US2024400563A1Substituted pyridopyrimidinonyl compounds useful as t cell activatorsBRISTOL MYERS SQUIBB CO·Filed 2024·Application pending·0 cites
- 0978US9884868B2TGF-beta inhibitorsRIGEL PHARMACEUTICALS INC·Filed 2016·Granted Feb 6, 2018·2 cites·36 claims
- 1074US9145419B2Imidazopyridazinyl compoundsVELAPARTHI UPENDER·Filed 2011·Granted Sep 29, 2015·3 cites·8 claims
- 1174US7470696B2Tyrosine kinase inhibitorsBRISTOL MYERS SQUIBB CO·Filed 2007·Granted Dec 30, 2008·1 cites·14 claims
- 1274US7081454B2Tyrosine kinase inhibitorsBRISTOL MYERS SQUIBB CO·Filed 2002·Granted Jul 25, 2006·6 cites·20 claims
- 1374US2023151007A1Substituted pyridopyrimidinonyl compounds useful as t cell activatorsBRISTOL MYERS SQUIBB CO·Filed 2022·Application pending·0 cites
- 1471US8212031B2Pyrrolotriazine kinase inhibitorsVELAPARTHI UPENDER·Filed 2009·Granted Jul 3, 2012·1 cites·9 claims
- 1570US7189716B2Tyrosine kinase inhibitorsBRISTOL MYERS SQUIBB CO·Filed 2004·Granted Mar 13, 2007·4 cites·11 claims
- 1667US11713316B2Substituted naphthyridinone compounds useful as T cell activatorsBRISTOL MYERS SQUIBB CO·Filed 2021·Granted Aug 1, 2023·0 cites·11 claims
- 1767US8916553B2Sulfonamide compounds useful as CYP17 inhibitorsAUSTIN JOEL FRANCIS·Filed 2011·Granted Dec 23, 2014·2 cites·14 claims
- 1866US11584747B2Substituted pyridopyrimidinonyl compounds useful as T cell activatorsBRISTOL MYERS SQUIBB CO·Filed 2020·Granted Feb 21, 2023·0 cites·33 claims
- 1966US9475817B2Pyrazole substituted imidazopyrazines as casein kinase 1 d/e inhibitorsBRISTOL MYERS SQUIBB CO·Filed 2013·Granted Oct 25, 2016·1 cites·12 claims
- 2066US9273058B2Substituted pyrazolo-piperazines as casein kinase 1 δ/ε inhibitorsBRISTOL MYERS SQUIBB CO·Filed 2014·Granted Mar 1, 2016·1 cites·14 claims
- 2161US10954238B1Substituted naphthyridinone compounds useful as T cell activatorsBRISTOL MYERS SQUIBB CO·Filed 2020·Granted Mar 23, 2021·0 cites·11 claims
- 2261US8148522B2Intermediate useful in preparing certain pyrrolotriazine compounds and a process for making the intermediateVELAPARTHI UPENDER·Filed 2008·Granted Apr 3, 2012·0 cites·5 claims
- 2358US11352360B2TGF-beta inhibitorsRIGEL PHARMACEUTICALS INC·Filed 2019·Granted Jun 7, 2022·0 cites·21 claims
- 2458US2024217982A1Kras inhibitorsBRISTOL MYERS SQUIBB CO·Filed 2022·Application pending·0 cites
- 2558US2024317769A1Kras g12d inhibitorsBRISTOL MYERS SQUIBB CO·Filed 2022·Application pending·0 cites
- 2656US12454531B2Substituted piperazine derivatives useful as T cell activatorsBRISTOL MYERS SQUIBB CO·Filed 2020·Granted Oct 28, 2025·0 cites·13 claims
- 2756US9242967B2Substituted bicyclic heteroaryl compoundsBRISTOL MYERS SQUIBB CO·Filed 2015·Granted Jan 26, 2016·0 cites·11 claims
- 2856US8592579B2Pyrrolotriazine kinase inhibitorsWITTMAN MARK D·Filed 2012·Granted Nov 26, 2013·0 cites·1 claims
- 2955US10287295B2TGF-β inhibitorsRIGEL PHARMACEUTICALS INC·Filed 2018·Granted May 14, 2019·0 cites·20 claims
- 3055US2024108654A1Combination of a t cell therapy and a dgk inhibitorJUNO THERAPEUTICS INC·Filed 2022·Application pending·0 cites
- 3154US11964973B2Substituted bicyclic compounds useful as T cell activatorsBRISTOL MYERS SQUIBB CO·Filed 2020·Granted Apr 23, 2024·0 cites·11 claims
- 3254US2023061608A1Substituted quinolinonyl piperazine compounds useful as t cell activatorsBRISTOL MYERS SQUIBB CO·Filed 2020·Application pending·0 cites
- 3353US12492172B2Substituted quinazolinyl compounds useful as T cell activatorsBRISTOL MYERS SQUIBB CO·Filed 2020·Granted Dec 9, 2025·0 cites·12 claims
- 3453US9598423B2Substituted 4,5,6,7-tetrahydropyrazolo[1,5-A]pyrazine derivatives as casein kinase 1 D/E inhibitorsBRISTOL MYERS SQUIBB CO·Filed 2014·Granted Mar 21, 2017·0 cites·13 claims
- 3552US2023086933A1Substituted heteroaryl compounds useful as t cell activatorsBRISTOL MYERS SQUIBB CO·Filed 2020·Application pending·0 cites
- 3651US2023089255A1Combinations of dgk inhibitors and checkpoint antagonistsBRISTOL MYERS SQUIBB CO·Filed 2020·Application pending·0 cites
- 3749US8415340B2Triazine kinase inhibitorsVELAPARTHI UPENDER·Filed 2008·Granted Apr 9, 2013·0 cites·14 claims
- 3843US10961239B2TGF beta receptor antagonistsBRISTOL MYERS SQUIBB CO·Filed 2018·Granted Mar 30, 2021·0 cites·11 claims
- 3942US2016122358A1Novel substituted pyrazolo-piperazines as casein kinase 1 d/e inhibitorsBRISTOL MYERS SQUIBB CO·Filed 2016·Application pending·0 cites
- 4042US2018250303A1Tgf beta receptor antagonistsBRISTOL MYERS SQUIBB CO·Filed 2016·Application pending·0 cites
- 4138US8673922B2Azaindazole compoundsVELAPARTHI UPENDER·Filed 2011·Granted Mar 18, 2014·0 cites·8 claims
- 4237US9981944B2GDF-8 inhibitorsRIGEL PHARMACEUTICALS INC·Filed 2016·Granted May 29, 2018·0 cites·19 claims
- 4337US2019292179A1TGF Beta RECEPTOR ANTAGONISTSBRISTOL MYERS SQUIBB CO·Filed 2017·Application pending·0 cites
- 4428US9956220B2Imidazo-pyridazine derivatives as casein kinase 1 δ/ϵ inhibitorsBRISTOL MYERS SQUIBB CO·Filed 2015·Granted May 1, 2018·0 cites·11 claims
Join the waitlist — get patent alerts
Get an alert when Upender Velaparthi files or is granted a new patent.
We store only your email — no account needed. See our privacy policy.
Identity basis: PatentsView inventor disambiguation (2025Q4-odp release). How scoring works →